A phase I study of a TASK channel blocker in patients with obstructive sleep apnea
Latest Information Update: 05 Dec 2017
Price :
$35 *
At a glance
- Drugs Sleep apnoea therapeutics-Bayer (Primary)
- Indications Sleep apnoea syndrome
- Focus Adverse reactions
- 05 Dec 2017 New trial record